A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

NCT06230224 · OLYMPIA-4 Phase 3Active, not recruiting

Lead sponsor: Regeneron Pharmaceuticals (Industry)
Enrollment: 216 (actual)
Start date: 15 Feb 2024
Primary completion: 29 May 2028 (estimated)
Study completion: 29 May 2029
Last update posted: 11 May 2026

Design

Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel
Masking: None
Arms: 2

Interventions

Odronextamab Drug
Ifosfamide Drug
Carboplatin Drug
Etoposide Drug
Rituximab Drug
Dexamethasone Drug
Cisplatin Drug
Cytarabine Drug
Gemcitabine Drug

Conditions and primary outcome

B-Cell Non-Hodgkin Lymphoma (B-NHL)

Primary outcome

Event-free survival (EFS) as assessed by independent central review (ICR) (Assessed up to 3 years)

Posted results on ClinicalTrials.gov

Results posted on ClinicalTrials.gov: No

Results from company and journal sources

No editor-confirmed results are on record for this study.

Publications

No PubMed citation lists NCT06230224.

CT-VCA trial quality

Loading CT-VCA scores…

Data integrity

Compare what the registry, company releases, FDA documents and publications say about this study.

Drugs on HealthTrade

Odronextamab

Source

NCT06230224 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read 25 Oct 2026

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.

Nothing on this page is medical or investment advice.